Celtic Therapeutics has announced a name change to Auven Therapeutics effective 11th March 2013. The name change was made in order to overcome confusion related to other Celtic entities, which are not part of Auven. The rebrand reflects the company's mission to provide the gold standard in drug development, progressing promising therapeutic pharmaceutical candidates in areas of unmet medical need.
Auven has a portfolio of biologic and small-molecule therapeutic candidates, primarily comprising preclinical to mid-stage development programmes, for therapeutic indications including cancer, ophthalmic conditions, women's health and orphan diseases. It has ownership of or a majority interest in the therapeutic assets of ADC Therapeutics, Spirogen, Resolvyx and Kiacta, and a minority investment in Kolltan and Sprout Pharmaceuticals.